Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $462K | $2.72M | $0.00 | $0.00 | $1.03M | $1.63M |
| Revenue growth | — | 488.1% | -100.0% | — | — | 58.9% |
| Operating income | -$16.5M | -$51.6M | -$63.5M | -$66.1M | -$53.3M | -$38.3M |
| Operating margin | -3581.0% | -1899.1% | — | — | -5186.2% | -2346.0% |
| Net income | -$16.7M | -$8.33M | -$30.6M | -$34.0M | -$30.0M | -$29.7M |
| Net margin | -3615.4% | -306.6% | — | — | -2920.0% | -1817.1% |
| EPS (diluted) | — | -$0.43 | -$1.28 | -$1.33 | -$1.05 | -$0.45 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$15.0M | -$32.2M | -$46.5M | -$51.2M | -$35.5M | -$18.7M |
| Capital expenditures | $1.20M | $506K | $1.62M | $1.23M | $268K | $88.0K |
| Free cash flow | -$16.2M | -$32.8M | -$48.1M | -$52.5M | -$35.8M | -$18.8M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $73.1M | $117M | $27.0M | $5.86M | $3.76M | $18.6M |
| Total assets | $79.4M | $124M | $108M | $57.9M | $36.6M | $58.6M |
| Total liabilities | $8.04M | $2.64M | $34.0M | $32.5M | $33.1M | $17.1M |
| Long-term debt | $2.41M | $0.00 | $29.1M | $24.5M | $9.61M | $0.00 |
| Shareholders' equity | -$113M | $47.4M | $36.9M | $12.9M | $1.99M | $33.0M |
| Retained earnings | -$114M | -$8.33M | -$38.9M | -$72.9M | -$103M | -$133M |
| Shares (wtd avg diluted) | — | 19.5B | 23.8B | 25.5B | 28.5B | 66.1B |
Every figure is extracted from Rani Therapeutics Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.